Drug intelligence / Profile preview

Aurigene CBL-B inhibitor

Development stage: Preclinical
Lead developer: Aurigene Oncology
Modality: Small Molecules
Administration: Oral

Overview

Aurigene Discovery Technologies is developing a small molecule inhibitor of the E3 ubiquitin ligase **CBL-B** (Casitas B-lineage lymphoma proto-oncogene B) for the treatment of solid tumors. CBL-B is a critical intracellular checkpoint that negatively regulates the activation of T cells and NK cells. By inhibiting CBL-B, the drug aims to lower the threshold for immune cell activation and prevent exhaustion, thereby enhancing the anti-tumor immune response. This approach is designed to overcome immune suppression within the tumor microenvironment and is currently in the preclinical stage of development.

Other names: Aurigene CBL-B small molecule modulatorAurigene CBL-B small molecule inhibitor

Targets

CBLB (CBL-B)

Beyond the preview

Go deeper on Aurigene CBL-B inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aurigene CBL-B inhibitor.

Explore the full profile